US2010063070A1PendingUtilityA1

Combination for use in the treatment of inflammatory disorders

Assignee: RAUD JOHANPriority: Dec 18, 2006Filed: Dec 16, 2007Published: Mar 11, 2010
Est. expiryDec 18, 2026(~0.4 yrs left)· nominal 20-yr term from priority
Inventors:Johan Raud
A61P 37/00A61P 37/02A61P 9/00A61P 9/10A61P 25/00A61P 25/06A61P 31/04A61P 29/00A61P 11/06A61K 31/366A61P 1/04A61P 11/00A61K 31/22A61P 19/02A61K 31/505A61K 45/06A61K 31/405A61K 31/517A61P 17/06A61K 31/40A61K 31/47A61K 31/519
42
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

There is provided combination products comprising (a) pemirolast, or a pharmaceutically-acceptable salt or solvate thereof; and (b) a statin, or a pharmaceutically-acceptable salt or solvate thereof. Such combination products find particular utility in the treatment of atheresclerosis and related conditions.

Claims

exact text as granted — not AI-modified
1 . A combination product comprising:
 (a) pemirolast, or a pharmaceutically-acceptable salt or solvate thereof; and   (b) a statin, or a pharmaceutically-acceptable salt or solvate thereof.   
   
   
       2 . A combination product as claimed in  claim 1 , wherein the statin is selected from pitavastatin, fluvastatin, simvastatin, lovastatin, rosuvastatin, pravastatin and atorvastatin. 
   
   
       3 . A combination product as claimed in  claim 2 , wherein the statin is selected from simvastatin, rosuvastatin and atorvastatin. 
   
   
       4 . A combination product as claimed in  claim 3 , wherein the statin is selected from rosuvastatin and atorvastatin. 
   
   
       5 . A combination product as claimed in  claim 1 , which comprises a pharmaceutical formulation including pemirolast, or a pharmaceutically-acceptable salt or solvate thereof; a statin, or a pharmaceutically-acceptable salt or solvate thereof; and a pharmaceutically-acceptable adjuvant, diluent or carrier. 
   
   
       6 . A combination product as claimed in  claim 1 , which comprises a kit of parts comprising components:
 (A) a pharmaceutical formulation including pemirolast, or a pharmaceutically-acceptable salt or solvate thereof, in admixture with a pharmaceutically-acceptable adjuvant, diluent or carrier; and   (B) a pharmaceutical formulation including a statin, or a pharmaceutically-acceptable salt or solvate thereof, in admixture with a pharmaceutically-acceptable adjuvant, diluent or carrier,   which components (A) and (B) are each provided in a form that is suitable for administration in conjunction with the other.   
   
   
       7 . (canceled) 
   
   
       8 . A kit of parts according to  claim 6 , further comprising:
 (I) one of components (A) and (B); together with   (II) instructions to use that component in conjunction with the other of the two components.   
   
   
       9 . A combination product as claimed in  claim 1 , wherein the statin is not employed in the form of a statin lactone. 
   
   
       10 . A combination product as claimed in  claim 1 , wherein the statin employed is lovastatin lactone or simvastatin lactone. 
   
   
       11 . A kit of parts as claimed in  claim 6 , wherein components (A) and (B) are suitable for sequential, separate and/or simultaneous use in the treatment of an inflammatory disorder. 
   
   
       12 . (canceled) 
   
   
       13 . A method of treatment of an inflammatory disorder, which method comprises the administration of a combination product as defined in  claim 1 , to a patient in need of such treatment. 
   
   
       14 . A kit of parts as claimed in  claim 11 , wherein the disorder is selected from migraine, asthma, chronic obstructive pulmonary disease, Crohn's disease, multiple sclerosis, psoriasis, rheumatoid arthritis, systemic lupus erythematosus or ulcerative colitis. 
   
   
       15 . A kit of parts as claimed in  claim 11  wherein the disorder is atherosclerosis or an associated cardiovascular disorder. 
   
   
       16 . A kit of parts, as claimed in  claim 15 , wherein the disorder is atherosclerosis. 
   
   
       17 . A kit of parts, as claimed in  claim 15 , wherein the cardiovascular disorder associated with atherosclerosis is selected from an aortic aneurysm, arteriosclerosis, peripheral arterial occlusive disease, a coronary artery disease, a coronary disease, plaque rupture, atheroma rupture and/or instability, a vascular disease, an arterial disease, an ischemic disease, ischemia and stroke. 
   
   
       18 . A kit of parts, as claimed in  claim 17 , wherein the coronary artery disease is selected from angina pectoris, myocardial infarction and heart attack. 
   
   
       19 . A kit of parts, as claimed in  claim 17 , wherein the coronary disease is selected from a cardiac disease and a heart disease. 
   
   
       20 . A kit of parts, as claimed in  claim 17 , wherein the stroke is selected from cerebro-vascular accident and transient ischaemic attack. 
   
   
       21 . A kit of parts, as claimed in  claim 11 , wherein the patient has an acute coronary syndrome.

Join the waitlist — get patent alerts

Track US2010063070A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.